Clinical trial
Antineoplaston Therapy in Treating Patients With Metastatic, Recurrent, or…
NCT00003513 · Burzynski Research Institute, Other · Terminated
Key facts
| NCT number | NCT00003513 |
|---|---|
| Title | Antineoplaston Therapy in Treating Patients With Metastatic, Recurrent, or Refractory Neuroblastoma |
| Official title | Phase II Study of Antineoplastons A10 and AS2-1 In Patients With Neuroblastoma |
| Lead sponsor | Burzynski Research Institute, Other |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Neuroblastoma |
| Intervention type | Drug |
| Interventions | Antineoplaston therapy (Atengenal + Astugenal) |
| Enrollment | 3 |
| Start date | Dec 16, 1996 |
| Primary completion | Mar 29, 1999 |
| Completion | Mar 29, 1999 |
| First posted | Jan 27, 2003 |
| Last update posted | Sep 28, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: